dr. howard burris discusses the mtor inhibitor everolimus for breast cancer
Published 12 years ago • 635 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
1:39
dr. burris discusses targeting the mtor pathway
-
2:48
dr. howard a. burris on everolimus: the impact, the toxicity and the nurses
-
1:36
dr. burris discusses the stratification of clinical trials
-
1:53
dr. burris on molecular profiling in breast cancer
-
0:35
copy of dr. burris on molecular profiling in breast cancer
-
2:06
dr. burris on recent advances in tnbc
-
8:33
bolero-2 trial: everolimus in metastatic breast cancer
-
0:34
copy of dr. burris discusses promise of t-dm1 in her2 breast cancer
-
2:08
dr. jose baselga compares the mtor inhibitors temsirolimus and everolimus
-
1:40
dr. burris on remaining challenges in treating her2 breast cancer
-
1:09
dr. burris discusses promise of t-dm1 in her2 breast cancer
-
4:29
managing the toxicity of everolimus in breast cancer
-
3:43
second-line everolimus in metastatic breast cancer
-
2:35
dr. burris on updated monaleesa-2 trial results for hr breast cancer
-
7:02
the ongoing role of everolimus in er-positive mbc
-
7:37
next steps for everolimus in er-positive metastatic breast cancer
-
1:04
dr. burris discusses pathological cr as an endpoint
-
10:55
san antonio roundtable, part 4: everolimus in clinical practice, a new cdk inhibitor
-
1:03
dr. carey on everolimus in metastatic breast cancer